Work at Shanghai Haihe Biopharma Co. Ltd. has led to the development of pyrimidine-2(1H)-one-fused bicyclic compounds acting as S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors and thus reported to be useful for the treatment of cancer.